Pharmaceutical Production Inside Merck KGaA Health Care Laboratory
An employee monitors Euthyrox hypothyroid treatment tablets as they pass through a blister pack packaging machine inside Merck KGaA's pharmaceutical laboratories at the company's headquarters in Darmstadt, Germany, on Thursday, Nov. 3, 2016. Merck and Idemitsu Kosan Co Ltd. today signed an agreement to allow each party to use the other's organic light-emitting diode (OLED) material-related patents in certain areas. Photographer: Martin Leissl/Bloomberg via Getty ImagesMartin Leissl — Bloomberg via Getty Images
  • Previous Rank
    72
  • Revenues ($M)
    39807
  • Revenue Percent Change
    0.8
  • Profits ($M)
    3920
  • Profits Percent Change
    -11.8
  • Assets ($M)
    95377
  • Employees
    68000
  • Market Value — as of March 31, 2017 ($M)
    174454

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant's wide-ranging portfolio was crucial to that haul but the company's next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb's competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Company Info

CEOKenneth C. Frazier
CEO TitleChairman, President & Chief Executive Officer
SectorHealth Care
IndustryPharmaceuticals
HQ LocationKenilworth, NJ
Websitewww.merck.com
Years on Fortune 500 List23
Employees68,000

Key Financials (Last Fiscal Year)

Revenues ($M)$39,807
Profits ($M)$3,920
Assets ($M)$95,377
Total Stockholder Equity ($M)$40,088
Market Value — as of March 31, 2017 ($M)$174,454

Profit Ratios

Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1
EPS % Change (from 2015)-9.6%
EPS % Change (5 year annual rate)-6.9%
EPS % Change (10 year annual rate)-3.6%

Total Return

Total Return to Investors (2016)15.1%
Total Return to Investors (5 year, annualized)13.2%
Total Return to Investors (10 year, annualized)7%